Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Entera Bio Ltd. (ENTX)
USD1.78
+0.16 (+9.88%)
IL NASDAQ Healthcare Biotechnology
Address
Kiryat Hadassah Minrav Building 9112002
Jerusalem, IL
Jerusalem, IL
CEO
Miranda J. Toledano
Website
enterabio.com
IPO
2018-06-28
CIK 1638097 ISIN IL0011429839
Also trades on
NASDAQ Capital Market · ENTX (USD)
NASDAQ Capital Market · ENTXW (USD)
Description
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.78
+0.16 (+9.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.49
Float Shares
32.24M
Free Float %
69.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.00% | -6.40% | +1.74% | -23.03% | -59.79% | -39.69% | -45.58% | +24.47% | -61.51% | -81.37% | -81.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
1.78
DCF (Unlevered)
0.14
-92.2%
DCF (Levered)
0.14
-92.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.98
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-76.8% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+0.0% Q1'26: +218.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-24,457.1%
-
EBIT margin Biotechnology: +0.0%-27,450.0%
-
ROIC Biotechnology: -16.1%-177.8% Q1'26: -202.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+22.7% Q1'26: +10.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
236.0K
est: -134.0K (+276.1%)
|
365.0K
est: 144.0K (+153.5%)
|
571.0K
est: 543.0K (+5.2%)
|
134.0K
est: 178.0K (-24.7%)
|
—
est: 57.0K (-100.0%)
|
181.0K
est: 139.0K (+30.2%)
|
42.0K
est: 42.0K (+0.0%)
|
54.58M
54.58M – 54.58M
+129,852.4% YoY
|
5.6K
5.6K – 5.6K
-100.0% YoY
|
| EBITDA |
-10.47M
est: 80.4K (-13,126.1%)
|
-11.11M
est: -86.4K (-12,753.0%)
|
-12.16M
est: -325.8K (-3,633.6%)
|
-12.87M
est: -7.87M (-63.6%)
|
-8.80M
est: -34.2K (-25,642.7%)
|
-9.54M
est: -83.4K (-11,337.6%)
|
-11.50M
est: -25.2K (-45,531.0%)
|
-32.75M
-32.75M – -32.75M
-129,852.4% YoY
|
-3.4K
-3.4K – -3.4K
+100.0% YoY
|
| EBIT |
-10.71M
est: 80.4K (-13,422.1%)
|
-11.17M
est: -86.4K (-12,825.9%)
|
-12.22M
est: -325.8K (-3,649.8%)
|
-12.93M
est: -6.90M (-87.5%)
|
-8.86M
est: -34.2K (-25,806.4%)
|
-9.59M
est: -83.4K (-11,392.8%)
|
-11.53M
est: -25.2K (-45,650.0%)
|
-32.75M
-32.75M – -32.75M
-129,852.4% YoY
|
-3.4K
-3.4K – -3.4K
+100.0% YoY
|
| Net Income |
-10.80M
est: -30.50M (+64.6%)
|
-11.22M
est: -21.08M (+46.8%)
|
-12.19M
est: -39.66M (+69.3%)
|
-13.07M
est: -10.62M (-23.1%)
|
-8.89M
est: -11.93M (+25.5%)
|
-9.54M
est: -12.93M (+26.2%)
|
-11.44M
est: -12.93M (+11.6%)
|
-19.40M
-19.40M – -19.40M
-50.0% YoY
|
-26.33M
-26.33M – -26.33M
-35.7% YoY
|
| SGA |
4.28M
est: -2.86M (+249.9%)
|
4.85M
est: 3.07M (+58.1%)
|
5.69M
est: 11.57M (-50.8%)
|
7.25M
est: 3.79M (+91.2%)
|
4.43M
est: 2.56M (+72.9%)
|
5.10M
est: 6.25M (-18.5%)
|
5.53M
est: 1.89M (+192.6%)
|
2.45B
2.45B – 2.45B
+129,852.4% YoY
|
253.9K
253.9K – 253.9K
-100.0% YoY
|
| EPS |
-0.90
est: -0.81 (-11.1%)
|
-0.54
est: -0.56 (+3.6%)
|
-0.47
est: -1.05 (+55.4%)
|
-0.45
est: -0.49 (+8.2%)
|
-0.31
est: -0.26 (-20.1%)
|
-0.25
est: -0.28 (+10.7%)
|
-0.25
est: -0.28 (+10.7%)
|
-0.42
-0.42 – -0.42
-50.0% YoY
|
-0.57
-0.57 – -0.57
-35.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-22.41M
OE per share TTM
-0.48
Owner's Yield
-36.10%
Maintenance CapEx ratio
2.04%
Maint CapEx / Avg PPE
170.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
52.5K
Insider transactions (90d)
3
Beneficial owners (>5%)
19
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zeev Bronfeld | 3.29M | 18.42% | — | 3.29M | — | — | IN | Israel | 2020-02-18 | ↗ |
| 2 | D.N.A Biomedical Solutions Ltd. | 3.26M | 18.23% | — | 3.26M | — | — | CO | Israel | 2020-02-18 | ↗ |
| 3 | Peter Kolchinsky | 2.35M | 9.90% | — | 2.35M | — | — | HC, IN | Delaware | 2021-06-30 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 2.35M | 9.90% | — | 2.35M | — | — | PN | Delaware | 2021-06-30 | ↗ |
| 5 | RA Capital Management, L.P. | 2.35M | 9.90% | — | 2.35M | — | — | IA, PN | Delaware | 2021-06-30 | ↗ |
| 6 | Rajeev Shah | 2.35M | 9.90% | — | 2.35M | — | — | HC, IN | Delaware | 2021-06-30 | ↗ |
| 7 | Knoll Capital Management, LP | 1.74M | 8.30% | — | 1.74M | — | 1.74M | PN | Delaware | 2021-02-16 | ↗ |
| 8 | Menahem Ehud Raphael | 1.48M | 8.09% | 1.48M | — | 1.48M | — | IN | Israel | 2020-03-09 | ↗ |
| 9 | The estate of the late Menahem Ehud Raphael | 1.39M | 6.51% | 1.39M | — | 1.39M | — | IN | Israel | 2021-02-16 | ↗ |
| 10 | CENTILLION FUND, INC. | 1.13M | 5.37% | 1.13M | — | 1.13M | — | CO | SAINT LUCIA | 2021-02-10 | ↗ |
| 11 | 4 GP, Limited Partnership | 853.5K | 7.30% | — | 853.5K | — | 853.5K | PN | Israel | 2019-02-14 | ↗ |
| 12 | Kariv | 853.5K | 7.30% | — | 853.5K | — | 853.5K | IN | Israel | 2019-02-14 | ↗ |
| 13 | Management 4 GP Ltd. | 853.5K | 7.30% | — | 853.5K | — | 853.5K | CO | Israel | 2019-02-14 | ↗ |
| 14 | Nussbaum | 853.5K | 7.30% | — | 853.5K | — | 853.5K | IN | Israel | 2019-02-14 | ↗ |
| 15 | Phillip Schwartz | 691.1K | 5.70% | 691.1K | — | 691.1K | — | IN | United States | 2019-02-08 | ↗ |
| 16 | Partnership | 420.9K | 3.60% | 420.9K | — | 420.9K | — | PN | Israel | 2019-02-14 | ↗ |
| 17 | (China) IV, L.P. | 227.5K | 2.00% | 227.5K | — | 227.5K | — | PN | Islands | 2019-02-14 | ↗ |
| 18 | (Cayman) IV, L.P. | 205.0K | 1.80% | 205.0K | — | 205.0K | — | PN | Islands | 2019-02-14 | ↗ |
| 19 | Capital Point Ltd. | — | 0.00% | — | — | — | — | CO | Israel | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
2
-19 vs prev Q
New positions
1
Closed positions
20
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | KNOLL CAPITAL MANAGEMENT, LLC | 5.88M +— (+0.0%) | 11.41M +117.6K (+1.0%) | 12.49% -0.068 pp | 5.23% -0.818 pp | USD2.57 -24.5% | 31 qtrs — |
| 2 | POINT72 ASSET MANAGEMENT, L.P. | 1.19M +15.2K (+1.3%) | 2.32M +53.1K (+2.3%) | 2.53% +0.019 pp | 0.00% -0.001 pp | USD1.70 +14.1% | 4 qtrs — |
| 3 | MARSHALL WACE, LLP | 627.3K +— (+0.0%) | 1.22M +12.5K (+1.0%) | 1.33% -0.007 pp | 0.00% 0.000 pp | USD1.92 +1.0% | 2 qtrs — |
| 4 | SCHONFELD STRATEGIC ADVISORS LLC | 596.6K +29.6K (+5.2%) | 1.16M +68.8K (+6.3%) | 1.27% +0.056 pp | 0.01% -0.001 pp | USD1.77 +9.6% | 7 qtrs — |
| 5 | PARKMAN HEALTHCARE PARTNERS LLC | 275.1K -5.7K (-2.0%) | 533.6K -5.5K (-1.0%) | 0.58% -0.015 pp | 0.05% -0.005 pp | USD1.76 +10.2% | 7 qtrs — |
| 6 | NORTHERN TRUST CORP | 148.7K +— (+0.0%) | 288.4K +3.0K (+1.0%) | 0.32% -0.002 pp | 0.00% +0.000 pp | USD2.12 -8.5% | 5 qtrs — |
| 7 | — | 135.3K +135.3K (+100.0%) | 262.5K +262.5K (+100.0%) | 0.29% +0.287 pp | 0.20% +0.200 pp | USD1.94 +0.0% | 1 qtrs NEW |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 108.0K +19.6K (+22.2%) | 209.5K +39.8K (+23.4%) | 0.23% +0.041 pp | 0.00% +0.000 pp | USD1.40 +38.6% | 14 qtrs — |
| 9 | JANE STREET GROUP, LLC | 74.1K +43.5K (+142.6%) | 143.7K +85.1K (+145.1%) | 0.16% +0.092 pp | 0.00% +0.000 pp | USD1.93 +0.5% | 3 qtrs — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 64.9K -2.3K (-3.4%) | 125.9K -3.1K (-2.4%) | 0.14% -0.006 pp | 0.00% +0.000 pp | USD1.95 -0.5% | 8 qtrs — |
| 11 | SIGNATURE ESTATE & INVESTMENT ADVISORS LLC | 47.3K +— (+0.0%) | 91.8K +946.0 (+1.0%) | 0.10% -0.001 pp | 0.00% 0.000 pp | USD1.90 +2.1% | 6 qtrs — |
| 12 | HIGHTOWER ADVISORS, LLC | 43.1K +25.0K (+137.8%) | 83.7K +48.9K (+140.3%) | 0.09% +0.053 pp | 0.00% +0.000 pp | USD1.84 +5.4% | 11 qtrs — |
| 13 | CITADEL ADVISORS LLC | 40.2K +252.0 (+0.6%) | 78.0K +1.3K (+1.7%) | 0.09% +0.000 pp | 0.00% +0.000 pp | USD1.91 +1.6% | 3 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 21.1K +— (+0.0%) | 41.0K +422.0 (+1.0%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD5.33 -63.6% | 19 qtrs — |
| 15 | SUPERSTRING CAPITAL MANAGEMENT LP | 17.1K +17.1K (+100.0%) | 33.3K +33.3K (+100.0%) | 0.04% +0.036 pp | 0.02% +0.018 pp | USD1.94 +0.0% | 1 qtrs NEW |
| 16 | BANK OF AMERICA CORP /DE/ | 15.0K -6.0K (-28.6%) | 29.1K -11.2K (-27.8%) | 0.03% -0.013 pp | 0.00% +0.000 pp | USD1.74 +11.5% | 7 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 12.3K +12.3K (+100.0%) | 23.9K +23.9K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD1.94 +0.0% | 1 qtrs NEW |
| 18 | GSA CAPITAL PARTNERS LLP | 11.9K +11.9K (+100.0%) | 23.0K +23.0K (+100.0%) | 0.03% +0.025 pp | 0.00% +0.002 pp | USD1.94 +0.0% | 1 qtrs NEW |
| 19 | PNC FINANCIAL SERVICES GROUP, INC. | 10.0K +— (+0.0%) | 19.4K +200.0 (+1.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD2.37 -18.1% | 16 qtrs — |
| 20 | GROUP ONE TRADING, L.P. | 51.00 +— (+0.0%) | 99.00 +1.0 (+1.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.71 +173.2% | 10 qtrs — |
| 21 | UBS GROUP AG | 17.00 -10.4K (-99.8%) | 33.00 -20.0K (-99.8%) | 0.00% -0.022 pp | 0.00% +0.000 pp | USD1.88 +3.2% | 3 qtrs — |
| 22 | BESSEMER GROUP INC | — -140.8K (-100.0%) | — -270.0K (-100.0%) | 0.00% -0.301 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 23 | XTX TOPCO LTD | — -10.8K (-100.0%) | — -20.7K (-100.0%) | 0.00% -0.023 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
| 24 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -2.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
219.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+218,978
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Yaacov-Garbeli Dana | Officer | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 58,394 | 0.00 | — | 171,441 | I | ↗ |
| 2026-05-07 | Galitzer Hillel | Officer | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 72,993 | 0.00 | — | 163,566 | D | ↗ |
| 2026-05-07 | Burshtein Gregory | Officer | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 87,591 | 0.00 | — | 189,033 | D | ↗ |
| 2026-03-09 | Germano Geno J | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 20,000 | 1.30 | 26.0K | 40,000 | D | ↗ |
| 2026-03-05 | Ellis Sean | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 10,000 | 1.23 | 12.3K | 188,098 | D | ↗ |
| 2026-02-10 | Taitel Haya | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 7,500 | 1.48 | 11.1K | 0 | D | ↗ |
| 2026-02-10 | Germano Geno J | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 20,000 | 1.49 | 29.8K | 0 | D | ↗ |
| 2026-02-09 | Ellis Sean | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 18,000 | 1.24 | 22.3K | 178,098 | D | ↗ |
| 2026-02-04 | Germano Geno J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-01 | Taitel Haya | Director | A-Award | A | Stock Option (right to buy) | 33,505 | 1.94 | 65.0K | 33,505 | D | ↗ |
| 2026-01-01 | OSTROV GERALD M | Director | A-Award | A | Stock Option (right to buy) | 33,505 | 1.94 | 65.0K | 33,505 | D | ↗ |
| 2026-01-01 | Malca Yonatan | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 30,157 | 0.00 | — | 77,416 | D | ↗ |
| 2026-01-01 | LIEBERMAN GERALD M | Director | A-Award | A | Stock Option (right to buy) | 33,505 | 1.94 | 65.0K | 33,505 | D | ↗ |
| 2026-01-01 | Ellis Sean | Director | A-Award | A | Stock Option (right to buy) | 33,505 | 1.94 | 65.0K | 33,505 | D | ↗ |
| 2025-12-29 | Toledano Miranda Jayne | Director / Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 11,000 | 1.81 | 19.9K | 426,575 | D | ↗ |
| 2025-07-16 | Yaacov-Garbeli Dana | Officer | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 26,316 | 0.00 | — | 113,047 | I | ↗ |
| 2025-07-16 | Toledano Miranda Jayne | Director / Officer | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 136,842 | 0.00 | — | 371,715 | D | ↗ |
| 2025-07-16 | Burshtein Gregory | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 2.28 | 456.0K | 200,000 | D | ↗ |
| 2025-05-08 | Gautam Leslie Velka | Officer | — | — | Stock Option (right to buy) | 60,000 | 2.28 | 136.8K | 0 | D | ↗ |
| 2025-04-28 | Galitzer Hillel | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.28 | 228.0K | 100,000 | D | ↗ |
| 2025-04-01 | LIEBERMAN GERALD M | Director | M-Exempt | A | Ordinary Shares, par value NIS 0.0000769 per share | 23,952 | 1.00 | 24.0K | 300,160 | D | ↗ |
| 2025-01-15 | Taitel Haya | Director | A-Award | A | Stock Option (right to buy) | 28,509 | 2.28 | 65.0K | 28,509 | D | ↗ |
| 2025-01-15 | OSTROV GERALD M | Director | A-Award | A | Stock Option (right to buy) | 28,509 | 2.28 | 65.0K | 28,509 | D | ↗ |
| 2025-01-15 | Malca Yonatan | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 8,216 | 0.00 | — | 47,259 | D | ↗ |
| 2025-01-15 | LIEBERMAN GERALD M | Director | A-Award | A | Stock Option (right to buy) | 28,509 | 2.28 | 65.0K | 28,509 | D | ↗ |
| 2025-01-15 | Ellis Sean | Director | A-Award | A | Stock Option (right to buy) | 28,509 | 2.28 | 65.0K | 28,509 | D | ↗ |
| 2024-11-14 | Knoll Capital Management, LLC | 10% Owner | — | — | Ordinary Shares, par value NIS 0.0000769 per share | 0 | 0.00 | — | 5,534,275 | D | ↗ |
| 2024-10-02 | Taitel Haya | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 7,278 | 0.00 | — | 57,728 | D | ↗ |
| 2024-10-02 | OSTROV GERALD M | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 8,452 | 0.00 | — | 38,898 | D | ↗ |
| 2024-10-02 | Malca Yonatan | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 8,639 | 0.00 | — | 39,043 | D | ↗ |
| 2024-10-02 | LIEBERMAN GERALD M | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 11,269 | 0.00 | — | 265,491 | D | ↗ |
| 2024-10-02 | Ellis Sean | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 7,466 | 0.00 | — | 127,627 | D | ↗ |
| 2024-08-27 | Taitel Haya | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 15,335 | 0.00 | — | 50,450 | — | ↗ |
| 2024-08-27 | OSTROV GERALD M | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 20,446 | 0.00 | — | 30,446 | — | ↗ |
| 2024-08-27 | Malca Yonatan | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 23,172 | 0.00 | — | 30,404 | — | ↗ |
| 2024-08-27 | LIEBERMAN GERALD M | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 27,261 | 0.00 | — | 254,222 | — | ↗ |
| 2024-08-27 | Ellis Sean | Director | A-Award | A | Ordinary Shares, par value NIS 0.0000769 per share | 18,061 | 0.00 | — | 120,161 | — | ↗ |
| 2024-07-31 | Toledano Miranda Jayne | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.99 | 995.0K | 500,000 | — | ↗ |
| 2024-05-28 | Burshtein Gregory | Officer | — | D | Stock Option (right to buy) | 18,900 | 2.14 | 40.4K | 0 | — | ↗ |
| 2024-04-19 | Yaacov-Garbeli Dana | Officer | A-Award | A | Stock Option (right to buy) | 130,000 | 1.99 | 258.7K | 130,000 | — | ↗ |
| 2024-04-19 | Galitzer Hillel | Officer | A-Award | A | Stock Option (right to buy) | 130,000 | 1.99 | 258.7K | 130,000 | — | ↗ |
| 2024-01-12 | Taitel Haya | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 9,500 | 0.99 | 9.4K | 35,115 | — | ↗ |
| 2024-01-10 | Taitel Haya | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 7,615 | 0.77 | 5.9K | 25,615 | — | ↗ |
| 2024-01-01 | Taitel Haya | Director | A-Award | A | Stock Option (right to buy) | 108,333 | 0.60 | 65.0K | 108,333 | — | ↗ |
| 2024-01-01 | OSTROV GERALD M | Director | A-Award | A | Stock Option (right to buy) | 108,333 | 0.60 | 65.0K | 108,333 | — | ↗ |
| 2024-01-01 | Mayron Ron | Director | A-Award | A | Stock Option (right to buy) | 108,333 | 0.60 | 65.0K | 108,333 | — | ↗ |
| 2024-01-01 | Malca Yonatan | Director | A-Award | A | Stock Option (right to buy) | 108,333 | 0.60 | 65.0K | 108,333 | — | ↗ |
| 2024-01-01 | LIEBERMAN GERALD M | Director | A-Award | A | Stock Option (right to buy) | 108,333 | 0.60 | 65.0K | 108,333 | — | ↗ |
| 2024-01-01 | GARCEAU ROGER | Director | A-Award | A | Stock Option (right to buy) | 108,333 | 0.60 | 65.0K | 108,333 | — | ↗ |
| 2024-01-01 | Ellis Sean | Director | A-Award | A | Stock Option (right to buy) | 108,333 | 0.60 | 65.0K | 108,333 | — | ↗ |
| 2023-12-22 | Toledano Miranda Jayne | Director / Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 23,952 | 0.71 | 17.0K | 110,752 | — | ↗ |
| 2023-12-22 | LIEBERMAN GERALD M | Director | P-Purchase | A | Warrants (right to buy) | 23,952 | 1.00 | 24.0K | 23,952 | — | ↗ |
| 2023-12-22 | Knoll Capital Management, LLC | 10% Owner | — | — | Warrants (right to buy) | 1,197,604 | 1.00 | 1.20M | 0 | D | ↗ |
| 2023-09-13 | Toledano Miranda Jayne | Director / Officer | A-Award | A | Stock Option (right to buy) | 350,000 | 0.80 | 278.3K | 350,000 | — | ↗ |
| 2023-09-13 | Taitel Haya | Director | A-Award | A | Stock Option (right to buy) | 33,368 | 0.81 | 27.0K | 33,368 | — | ↗ |
| 2023-08-22 | Taitel Haya | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 18,000 | 0.62 | 11.2K | 18,000 | — | ↗ |
| 2023-08-21 | LIEBERMAN GERALD M | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 20,000 | 0.59 | 11.8K | 214,209 | — | ↗ |
| 2023-08-21 | Ellis Sean | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 40,000 | 0.60 | 24.0K | 102,100 | — | ↗ |
| 2023-06-04 | Taitel Haya | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-24 | Yaacov-Garbeli Dana | Officer | A-Award | A | Stock Option (right to buy) | 190,000 | 0.80 | 151.1K | 190,000 | — | ↗ |
| 2023-04-24 | Santora Arthur C II | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 0.80 | 27.8K | 35,000 | — | ↗ |
| 2023-04-24 | Galitzer Hillel | Officer | A-Award | A | Stock Option (right to buy) | 210,000 | 0.80 | 167.0K | 210,000 | — | ↗ |
| 2023-04-04 | Toledano Miranda Jayne | Director / Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 30,000 | 1.01 | 30.3K | 86,800 | — | ↗ |
| 2023-01-02 | OSTROV GERALD M | Director | A-Award | A | Stock Option (right to buy) | 89,041 | 0.00 | — | 89,041 | — | ↗ |
| 2023-01-02 | Mayron Ron | Director | A-Award | A | Stock Option (right to buy) | 89,041 | 0.00 | — | 89,041 | — | ↗ |
| 2023-01-02 | Malca Yonatan | Director | A-Award | A | Stock Option (right to buy) | 89,041 | 0.00 | — | 89,041 | — | ↗ |
| 2023-01-02 | LIEBERMAN GERALD M | Director | A-Award | A | Stock Option (right to buy) | 89,041 | 0.00 | — | 89,041 | — | ↗ |
| 2023-01-02 | GARCEAU ROGER | Director | A-Award | A | Stock Option (right to buy) | 89,041 | 0.00 | — | 89,041 | — | ↗ |
| 2023-01-02 | Ellis Sean | Director | A-Award | A | Stock Option (right to buy | 89,041 | 0.00 | — | 89,041 | — | ↗ |
| 2022-11-14 | Yaacov-Garbeli Dana | Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 26,580 | 0.54 | 14.2K | 56,580 | — | ↗ |
| 2022-11-14 | LIEBERMAN GERALD M | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 34,000 | 0.57 | 19.4K | 194,209 | — | ↗ |
| 2022-11-11 | Yaacov-Garbeli Dana | Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 30,000 | 0.52 | 15.6K | 30,000 | — | ↗ |
| 2022-11-11 | Toledano Miranda Jayne | Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 50,000 | 0.53 | 26.6K | 56,800 | — | ↗ |
| 2022-11-11 | Ellis Sean | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 30,000 | 0.53 | 15.9K | 62,100 | — | ↗ |
| 2022-09-07 | Yaacov-Garbeli Dana | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-09-07 | Toledano Miranda Jayne | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 0.00 | — | 600,000 | — | ↗ |
| 2022-09-07 | Santora Arthur C II | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-07-21 | LIEBERMAN GERALD M | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 19,491 | 1.68 | 32.8K | 160,209 | — | ↗ |
| 2022-07-21 | Ellis Sean | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 14,900 | 1.64 | 24.4K | 32,100 | — | ↗ |
| 2022-03-31 | Galitzer Hillel | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-01-20 | Schwartz Phillip | Director / Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 10,000 | 2.53 | 25.3K | 607,410 | — | ↗ |
| 2022-01-19 | Ratan Ramesh | Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 10,000 | 2.44 | 24.4K | 10,000 | — | ↗ |
| 2022-01-18 | Mayron Ron | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 7,000 | 2.80 | 19.6K | 7,000 | — | ↗ |
| 2022-01-18 | LIEBERMAN GERALD M | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 700 | 2.81 | 2.0K | 2,200 | — | ↗ |
| 2022-01-18 | JAMAS SPIROS | Officer | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2022-01-18 | Ellis Sean | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 10,000 | 2.81 | 28.1K | 10,000 | — | ↗ |
| 2022-01-14 | Toledano Miranda Jayne | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 6,800 | 2.79 | 19.0K | 6,800 | — | ↗ |
| 2022-01-13 | OSTROV GERALD M | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 10,000 | 2.74 | 27.4K | 10,000 | — | ↗ |
| 2022-01-13 | Malca Yonatan | Director | P-Purchase | A | Ordinary Shares, par value NIS 0.0000769 per share | 7,232 | 2.74 | 19.8K | 7,232 | — | ↗ |
| 2022-01-01 | Yaacov-Garbeli Dana | Officer | — | D | Stock Option (right to buy) | 35,000 | 2.14 | 74.9K | 0 | — | ↗ |
| 2022-01-01 | Toledano Miranda Jayne | Director | A-Award | A | Stock Option (right to buy) | 107,557 | 2.82 | 302.8K | 107,557 | — | ↗ |
| 2022-01-01 | Schwartz Phillip | Director / Officer | — | D | Ordinary Shares, par value NIS 0.0000769 per share | 0 | 0.00 | — | 597,410 | — | ↗ |
| 2022-01-01 | Santora Arthur C II | Officer | — | D | Stock Option (right to buy) | 25,000 | 3.97 | 99.3K | 0 | — | ↗ |
| 2022-01-01 | Ratan Ramesh | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | OSTROV GERALD M | Director | A-Award | A | Stock Option (right to buy) | 35,852 | 2.82 | 100.9K | 35,852 | — | ↗ |
| 2022-01-01 | Mayron Ron | Director | A-Award | A | Stock Option (right to buy) | 107,557 | 2.82 | 302.8K | 107,557 | — | ↗ |
| 2022-01-01 | Malca Yonatan | Director | A-Award | A | Stock Option (right to buy) | 107,557 | 2.82 | 302.8K | 107,557 | — | ↗ |
| 2022-01-01 | LIEBERMAN GERALD M | Director | A-Award | A | Stock Option (right to buy) | 107,557 | 2.82 | 302.8K | 107,557 | — | ↗ |
| 2022-01-01 | JAMAS SPIROS | Director / Officer | — | — | Stock Option (right to buy) | 1,314,218 | 1.24 | 1.63M | 0 | D | ↗ |
| 2022-01-01 | GARCEAU ROGER | Director | — | D | Ordinary Shares, par value NIS 0.0000769 per share | 0 | 0.00 | — | 4,940 | — | ↗ |
| 2022-01-01 | Ellis Sean | Director | — | D | Ordinary Shares, par value NIS 0.0000769 per share | 0 | 0.00 | — | 7,200 | — | ↗ |
| 2018-07-02 | Ellis Sean | Director | — | D | Warrants (right to buy) | 3,000 | 5.85 | 17.6K | 0 | — | ↗ |
| 2017-11-04 | LIEBERMAN GERALD M | Director | — | D | Stock Option (right to buy) | 147,290 | 3.69 | 543.5K | 0 | — | ↗ |
| 2017-11-04 | GARCEAU ROGER | Director | — | D | Stock Option (right to buy) | 147,290 | 3.69 | 543.5K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-6.4K
Shares Outstanding
46.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Miranda Toledano Chief Executive Officer and director | 419.00 | — | — | 538.00 | — | — | 1.1K | 46.82% | ↗ |
| 2 | 2024 | Hillel Galitzer Chief Operating Officer | 259.00 | — | — | 175.00 | — | — | 531.00 | 32.96% | ↗ |
| 3 | 2024 | Dana Yaacov-Garbeli Chief Finance Officer | 226.00 | — | — | 158.00 | — | — | 438.00 | 36.07% | ↗ |
| 4 | 2023 | Miranda Toledano Chief Executive Officer and director | 338.00 | — | — | 532.00 | — | — | 950.00 | 56.00% | ↗ |
| 5 | 2023 | Hillel Galitzer Chief Operating Officer | 245.00 | — | — | 163.00 | — | — | 459.00 | 35.51% | ↗ |
| 6 | 2023 | Dana Yaacov-Garbeli Chief Finance Officer | 193.00 | — | — | 118.00 | — | — | 311.00 | 37.94% | ↗ |
| 7 | 2022 | Miranda Toledano Chief Executive Officer and director | 231.00 | — | — | 382.00 | — | — | 679.00 | 56.26% | ↗ |
| 8 | 2022 | Hillel Galitzer Chief Operating Officer | 287.00 | — | — | 234.00 | — | — | 621.00 | 37.68% | ↗ |
| 9 | 2022 | Dana Yaacov-Garbeli Chief Finance Officer | 193.00 | — | — | 156.00 | — | — | 381.00 | 40.94% | ↗ |
| 10 | 2021 | Spiros Jamas Former Chief Executive Officer | 392.00 | 751.00 | — | — | — | — | 1.1K | 0.00% | ↗ |
| 11 | 2021 | Dr. Phillip Schwartz Former President of RD | 453.00 | 183.00 | — | — | — | — | 685.00 | 0.00% | ↗ |
| 12 | 2021 | Dr. Hillel Galitzer Chief Operating Officer | 319.00 | — | — | 260.00 | — | — | 640.00 | 40.63% | ↗ |
| 13 | 2020 | Dr. Phillip Schwartz Former President of RD | 384.00 | 30.00 | — | 169.00 | — | — | 610.00 | 27.70% | ↗ |
| 14 | 2020 | Dr. Hillel Galitzer Chief Operating Officer | 292.00 | 50.00 | — | 168.00 | — | — | 527.00 | 31.88% | ↗ |
| 15 | 2020 | Spiros Jamas Former Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Miranda J. Toledano | Chief Executive Officer & Director | 562.0K | female |
| Hillel Galitzer | Chief Operating Officer | 307.0K | — |
| Gregory Burshtein | Chief of Research & Development | 254.0K | — |
| Dana Yaacov-Garbeli | Chief Financial Officer | 226.0K | female |
| Cherin Smith | Executive Vice President & Head of Clinical Operations | — | female |
| Constantin Itin | Head of Biopharmaceutics & Bioanalytics | — | — |
| Rachel Wagman | Chief Clinical Advisor | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ENTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
